Low IP-10/CXCL10 Levels are Associated with Good Responses to Lenalidomide Plus Low-Dose Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Nami Sakamoto,Yasuyuki Nagata,Yujiro Ito, Fumisato Takagi,Kotaro Nakano,Akari Yoda,Satoshi Uchiyama,Masamitsu Takaba,Miwa Adachi,Tomonari Takemura,Takaaki Ono

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2018）

引用 0|浏览17

暂无评分

摘要

Lenalidomide (Len) is widely used for the treatment of multiple myeloma (MM) exhibiting immunomodulatory properties. However, the relationship between in vivo immune status and clinical response to Len has not been elucidated.

查看译文

关键词

multiple myeloma,lenalidomide,Chemokine,Cytokine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要